Factors for the optimal selection of granulocyte colony-stimulating factor preparations and predictors for R-CHOP dose reductions/delays among patients with non-Hodgkin B-cell lymphoma (STOP FN in NHL 2 subanalysis)

Table 2 Dose reduction or delay after cycle 2

First cycle		Reduction after cycle 2, n (%)
G-CSF type	N	No		Yes
Overall	234	198 (84.6)		36 (15.4)
No G-CSF administration	60	52 (86.7)		8 (13.3)
Daily G-CSF	122	104 (85.2)		18 (14.8)
Pegfilgrastim	52	42 (80.8)		10 (19.2)
*Multivariate analysis* ^a: Dose reduction *Objective variable (0: no reduction, 1: dose reduction)*		Parameter estimate	Standard error	Odds ratio		p value
				OR	95% CI
FN onset in cycle 1 (absent, present)		1.7488	0.4672	5.748	2.301, 14.359	0.0002
Sex (male, female)		0.9693	0.4122	2.636	1.175, 5.914	0.0187
		Delay after cycle 2, n (%)
		No		Yes
Overall	234	137 (58.5)		97 (41.5)
No G-CSF administration	60	36 (60.0)		24 (40.0)
Daily G-CSF	122	68 (55.7)		54 (44.3)
Pegfilgrastim	52	33 (63.5)		19 (36.5)
*Multivariate analysis* ^b: Dose delay *Objective variable (0: absence of delay, 1: presence of delay)*		Parameter estimate	Standard error	Odds ratio		p value
				OR	95% CI
Hemoglobin (≥ 12 g/dL, < 12 g/dL)		0.8496	0.2801	2.339	1.351, 4.050	0.0024

CI confidence interval, G-CSF granulocyte colony-stimulating factor, OR odds ratio
^aVariables significantly associated with dose reduction were selected (p = 0.05)
^bVariables significantly associated with dose delay were selected (p = 0.05), the final model by stepwise selection

ISSN: 1471-2407